SCHEMBL6330717

SCHEMBL6330717

COc1cc2c(cc1OC)C(=C(Nc1ccc(Cl)cc1)c1ccccc1)C(=O)N2

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RET P07949 4/20 0.51
ATM Q13315 1/20 0.42
BRD4 O60885 3/20 0.41
BRD2 P25440 2/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
EGFR P00533 1/20 0.39
KDR P35968 1/20 0.38
NPC1 O15118 1/20 0.38
MAPT P10636 1/20 0.38
RAB9A P51151 1/20 0.38
CDYL2 Q8N8U2 1/20 0.38
CDYL Q9Y232 1/20 0.38
CDY1; CDY1B Q9Y6F8 1/20 0.38
CHEK1 O14757 1/20 0.38
TLK2 Q86UE8 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
CNR1 P21554 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5783036 1.00 RET (0.51) RETATMBRD4BRD2MEN1
SCHEMBL7477297 1.00 RET (0.51) RETATMBRD4BRD2MEN1
SCHEMBL5789112 0.92 RET (0.55) RETBRD4BRD2MEN1KMT2A
SCHEMBL5789109 0.92 RET (0.55) RETBRD4BRD2MEN1KMT2A
SCHEMBL5784002 0.90 RET (0.52) RETBRD4BRD2MEN1KMT2A
SCHEMBL5785525 0.90 RET (0.52) RETBRD4BRD2MEN1KMT2A
SCHEMBL5785496 0.90 RET (0.54) RETBRD4BRD2MEN1KMT2A
SCHEMBL5785531 0.90 RET (0.52) RETBRD4BRD2MEN1KMT2A
SCHEMBL5785488 0.90 RET (0.54) RETBRD4BRD2MEN1KMT2A
SCHEMBL6330841 0.90 RET (0.52) RETBRD4BRD2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009898-A1 New substituted indolinones, their manufacture and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-01-13 US disclosed
US-6794395-B1 Substituted indolinones, their manufacture and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009898-A1 New substituted indolinones, their manufacture and their use as medicaments CCNE1, CDK1, CCNI RET 154/4885ATM 735/4885BRD4 439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.